Compare CVKD & SRXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
SRX HealthSolutions Inc is an integrated, Canadian healthcare service provider operating within the specialty healthcare industry. It has developed a collaborative specialty healthcare network (the SRx Network) that strategically positions SRx to achieve business objectives. The SRx Network is comprised of 29 specialty pharmacies, 40 infusion clinics and injection sites, four clinical trials sites, patient support programs (PSP), an allied health team and nursing services, and a wholly owned Health Canada-accredited pharmaceutical wholesale and distribution facility located in Mississauga, Ontario. The SRx Network extends across all 10 Canadian provinces, making it one of the accessible providers of comprehensive, integrated and customized specialty healthcare services in Canada.